REG - IQ-AI Limited - Imaging Biometrics Expands Distribution

IQ-AIAnnouncement

20/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241120:nRST8473Ma&default-theme=true

RNS Number : 8473M  IQ-AI Limited  20 November 2024

November 20, 2024

IQ-AI Ltd

("IQ-AI" or the "Company")

Imaging Biometrics Expands Distribution

 

Imaging Biometrics (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd
(LSE: IQAI) has renewed its distribution agreement with GE HealthCare. This
agreement aims to expand the distribution of IB's advanced imaging solutions.
GE HealthCare will now sell IB Neuro and IB Delta T1 platforms directly to
both existing and new customers.

IB Neuro and IB Delta T1 maps are frequently used together to assist in
diagnosing, planning, and monitoring treatment response for brain tumor
patients. Delta T1 maps provide objective and rapid delineation of
contrast-enhancing regions, while IB Neuro generates magnetic resonance (MR)
perfusion images that accurately measure relative cerebral blood volume (rCBV)
using a proven contrast leakage correction algorithm. IB Neuro's rCBV
perfusion maps, derived from dynamic susceptibility contrast MRI (DSC-MRI),
are used for tumor assessment and have demonstrated the ability to distinguish
between true tumor regrowth and normal treatment effects. Both maps are
automatically generated and quantitative, allowing for direct longitudinal
comparison to assess tumoral changes.

"This global distribution arrangement allows us to introduce our products to
GE HealthCare's extensive customer base more rapidly," said Michael Schmainda,
CEO of IB. "We are excited about the immediate opportunities this creates for
GE HealthCare's sales and marketing teams."

Katie Anderson, Global MR Visualization Product Manager added, "We are excited
to expand our collaboration with Imaging Biometrics to enable access for our
customers to these clinically important capabilities."

The revised agreement aims to accelerate the adoption of IB's innovative
imaging solutions, benefiting healthcare providers and patients alike.

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

 IQ-AI Ltd

 Trevor Brown/Dr Musella/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Tel: 020 7220 9797

About Imaging Biometrics® LLC

IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on
delivering quantitative imaging platforms and therapeutics that transform how
clinicians diagnose and treat patients more efficiently and effectively. For
more information about Imaging Biometrics, visit the company's website at
www.imagingbiometrics.com (http://www.imagingbiometrics.com/) . Follow IB on
X @IQAI_IB.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRQKCBNPBDDKDD